PNC Financial Services Group
CCCC icon

PNC Financial Services Group’s C4 Therapeutics CCCC Stock Holding History

PNC Financial Services Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,316
Closed -$24.5K – 4934
2025
Q1 		$24.5K Sell
15,316
-452
-3% -$1.35K ﹤0.01% 3451
2024
Q4 		$56.8K Sell
15,768
-74
-0.5% -$368 ﹤0.01% 3033
2024
Q3 		$90.3K Buy
15,842
+2,905
+22% +$17.5K ﹤0.01% 2726
2024
Q2 		$59.8K Buy
+12,937
New +$77.2K ﹤0.01% 2935
2023
Q1 		– Sell
-2,000
Closed -$11.8K – 4698
2022
Q4 		$11.8K Hold
2,000
– – ﹤0.01% 3713
2022
Q3 		$18K Buy
+2,000
New +$20.8K ﹤0.01% 3488

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group's CCCC Position: Q2 2025 in Review

PNC Financial Services Group sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 15,316 shares — an estimated $24.5K sold.

PNC Financial Services Group first reported a position in CCCC in Q3 2022 and held it in 6 quarters. The position peaked at $90.3K in Q3 2024. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • PNC Financial Services Group reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 15,316 C4 Therapeutics shares in Q2 2025, an estimated $24.5K.
  • PNC Financial Services Group first reported a position in C4 Therapeutics in Q3 2022 and held it in 6 quarters.
  • PNC Financial Services Group's C4 Therapeutics position peaked at $90.3K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on PNC Financial Services Group's 13F filing for Q2 2025, filed 8 Aug 2025.